A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
G1 Therapeutics Inc.
Start Date
March 7, 2022
End Date
March 30, 2027
Administered By
Duke Cancer Institute
Awarded By
G1 Therapeutics Inc.
Start Date
March 7, 2022
End Date
March 30, 2027